VivoSeq
Oncology

Ependymoma

28

Pipeline Programs↗

7

Active Trials↗

16

Companies Involved↗

Ependymoma is an emerging landscape with 28 programs across 16 companies. The most active players are Plus Therapeutics, EMD Serono, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

75/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Plus Therapeutics

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

29 of 34 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%Cell therapy13%Gene therapy13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 35 pipeline programs.

Analysis

Trial Status

25

clinical trials

Completed12 · 48%
Active, not recruiting5 · 20%
Terminated4 · 16%
Unknown status2 · 8%
Not yet recruiting1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
Recruiting·CCentre Leon Berard·Phase 2/3·NCT02265770·536 enrolled
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00602667·293 enrolled
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
Active, not recruiting·CChildren's Cancer and Leukaemia Group·N/A·NCT00683319·50 enrolled
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
Active, not recruiting·Children's Oncology Group·Phase 1·NCT04903080·50 enrolled
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Active, not recruiting·Children's Oncology Group·Phase 3·NCT01096368·479 enrolled
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02125786·68 enrolled
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Not yet recruiting·PPlus Therapeutics·Phase 1·NCT07061626·56 enrolled
Carboplatin and Bevacizumab for Recurrent Ependymoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01295944·35 enrolled
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00883688·24 enrolled
Everolimus for Children With Recurrent or Progressive Ependymoma
Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT02155920·11 enrolled
Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas
Completed·MMayo Clinic·Phase 2·NCT00002876·35 enrolled
Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT04958486·4 enrolled
Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
Completed·SSociete Internationale d'Oncologie Pediatrique·Phase 2·NCT00004224·65 enrolled
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02940483·6 enrolled
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03572530·3 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)